<DOC>
	<DOCNO>NCT01380847</DOCNO>
	<brief_summary>The investigator show epithelial-to-mesenchymal transition ( EMT ) marker early protocol biopsy renal allograft predict progression fibrosis first year post-transplantation . The investigator develop non-invasive approach predict fibrosis substitute invasive allograft biopsy procedure , longitudinal assessment mRNA expression level gene implicate EMT/fibrogenesis inflammation urinary cell kidney transplant recipient first year post-transplantation .</brief_summary>
	<brief_title>Prediction Chronic Allograft Nephropathy</brief_title>
	<detailed_description>mRNA profile urinary cell fast evolve non-invasive substitute invasive biopsy procedure employ predict renal allograft outcomes . This technique successfully use develop biomarkers acute rejection , evaluate diagnosis allograft fibrosis . The progressive scarring process allograft , call chronic allograft nephropathy ( CAN ) , remain chief cause kidney transplant failure . We show immunohistochemistry epithelial change suggestive epithelial-to-mesenchymal transition ( EMT ) early protocol biopsy predict progression CAN first year post-transplantation . Our preliminary result suggest urinary cell mRNA profile alter kidney transplant recipient ( KTRs ) CAN . The purpose study evaluate urine KTRs first year post-transplantation ass whether mRNA level gene involve EMT/fibrogenesis diagnose predict CAN , identify patient risk chronic allograft dysfunction . The scientific underpinnings hypothesis provide ( ) data show urinary cell mRNAs predict pathological change ( i.e. , acute rejection ) renal allograft ; ( b ) previous study suggest CAN characterize altered urinary cell mRNA level . Our specific aim ( 1 ) investigate whether level 21 mRNAs encode gene involve EMT/fibrogenesis alloimmune response sensitive specific non-invasive diagnostic test CAN renal allograft ; ( 2 ) determine whether mRNA profile sequential urine specimen predict development CAN first year post-transplantation ; ( 3 ) determine whether mRNA profile sequential urine specimen predict subsequent development graft dysfunction assess estimate GFR 12 , 24 36 month transplantation . Eligible patient consecutive KTRs Necker Hospital one year ( nâ‰ˆ180 ) . Urine sample collect 1 , 3 , 6 , 9 12 month post-transplantation , 21 mRNAs involve EMT/fibrogenesis alloimmune response quantify PCR . Allograft fibrosis quantify image analysis , develop unit . Urinary cell mRNA profile correlate data protocol biopsy ( 3 month 1 year ) glomerular filtration rate ( GFR ) 1 3 year . Diagnostic prognostic accuracy mRNA level determine . The identification molecular marker CAN may allow early diagnosis CAN ( onset fix renal injury ) thus development specific therapeutic intervention .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Inclusion criterion : male female adult recipient patient undergo primary redo deceaseddonor livingdonor kidney transplantation ability provide inform consent Exclusion criterion : patient undergo combined organ transplantation Contraindication protocol allograft biopsy Inability unwillingness participant provide inform consent . HCV infect HIV infect</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Allograft</keyword>
	<keyword>Kidney failure</keyword>
	<keyword>Chronic allograft nephropathy</keyword>
	<keyword>Monitoring</keyword>
	<keyword>Urine</keyword>
</DOC>